Results 21 to 30 of about 6,725 (159)

Phytocannabinoid Compositions from Cannabis Act Synergistically with PARP1 Inhibitor against Ovarian Cancer Cells In Vitro and Affect the Wnt Signaling Pathway

Molecules, 2022
Ovarian cancer (OC) is the single most lethal gynecologic malignancy. Cannabis sativa is used to treat various medical conditions, and is cytotoxic to a variety of cancer types. We sought to examine the effectiveness of different combinations of cannabis
Nurit Shalev, Michelle Kendall, Seegehalli M. Anil, Sudeep Tiwari, Hadar Peeri, Navin Kumar, Eduard Belausov, Ajjampura C. Vinayaka, Hinanit Koltai   +8 more
doaj   +1 more source

Accelerating green heterocyclic synthesis: Convergence of AI, automation, and sustainable chemistry

Bulletin of the Korean Chemical Society, EarlyView.
Green heterocyclic synthesis and data‐driven tools such as AI, high‐throughput experimentation, continuous flow, and self‐driving laboratories have developed largely in parallel. This review connects them and asks how green metrics such as E‐factor and PMI might serve as explicit optimization targets rather than post‐hoc measures, toward sustainable ...
Noor Aisyah Ahmad Shah, Amirreza Mottafegh, Su‐Hyun Yoo, Jongwoon Kim, Minseon Byeon, Juhwan Noh, Yea‐Lee Lee, Jin Suk Myung, Gwang‐Noh Ahn   +8 more
wiley   +1 more source

Cross‐Regulation Between DNA Methylation and Circadian Clock Reprogramming in Ovarian Cancer: Mechanistic Insights, Biomarker Potential, and Therapeutic Implications

International Journal of Cancer, EarlyView.
ABSTRACT Early diagnosis remains challenging, recurrence rates remain high, and platinum resistance frequently develops in ovarian cancer (OC), collectively representing major barriers to long‐term patient survival. DNA methylation (DNAm), as a relatively stable yet dynamically modifiable epigenetic signature, can capture alterations in tumor states ...
Min Xing, Chang Zhou, Yi Tang, Shuhui Xu, Shasha Zhou, Weiai Liu, Huiping Liu   +6 more
wiley   +1 more source

PARP inhibitors combined with ionizing radiation induce different effects in melanoma cells and healthy fibroblasts

BMC Cancer, 2020
Background PARP inhibitors niraparib and talazoparib are FDA approved for special cases of breast cancer. PARP is an interesting repair protein which is frequently affected in cancer cells.
Verena Weigert, Tina Jost, Markus Hecht, Ilka Knippertz, Lucie Heinzerling, Rainer Fietkau, Luitpold V. Distel   +6 more
doaj   +1 more source

First-line maintenance therapy with niraparib in advanced platinum-sensitive ovarian cancer: two ‘long responder’ case reports and review of the current literature

Journal of International Medical Research, 2023
The standard of care for newly diagnosed advanced ovarian cancer is surgical cytoreduction plus platinum-based chemotherapy; however, recurrent disease frequently occurs after treatment.
Roger K. C. Ngan
doaj   +1 more source

Fertility counseling and preservation considerations in patients with gynecologic and non‐gynecologic BRCA and Lynch‐associated malignancies

International Journal of Gynecology &Obstetrics, EarlyView.
Abstract Lynch syndrome and BRCA‐mutation associated malignancies are fortunately rare. Affected patients have an increased risk of cancer diagnosis at a young age, often significantly overlapping with their reproductive years. In helping these patients, oncologists must navigate the following areas of care: cancer prevention, impact of cancer ...
Anna Weimer, Nadeem Abu‐Rustum, David Mutch, Mauricio Cuello, Angélica Fletcher, Hextan Y. S. Ngan, Nozomu Yanaihara, Rene Pareja, Christina Fotopoulou, Kenneth Ruzindana, Ka Yu Tse, Yana Zou, Neerja Bhatla, Ting‐Chang Chang, Munanchiso Ndukwe Iheme Jr, Jalid Sehouli, Nicole Conchin, Eva Chalas, Sarikapan Wilailak, Barbara Schmalfeldt, Alexander B. Olawaiye   +20 more
wiley   +1 more source

Physiologically‐Based Pharmacokinetic Modeling of the PARP Inhibitor Niraparib

CPT: Pharmacometrics & Systems Pharmacology
A physiologically‐based pharmacokinetic (PBPK) model of niraparib and its primary metabolite using a relevant virtual cancer population is reported here. A series of in vitro experiments using liver S9, microsomes, and hepatocytes with various inhibitors
Gareth J. Lewis, Roxanne C. Jewell, Anu Shilpa Krishnatry, Kunal S. Taskar   +3 more
doaj   +1 more source

Ovarian Cancer: Epidemiology, Disease Mechanisms, New Diagnosis and Treatment Strategies, and Research Directions

iNew Medicine, EarlyView.
ABSTRACT Ovarian cancer (OC) continues to be the deadliest gynecological malignancy and a significant cause of cancer‐related mortality among women worldwide. Standard treatment strategies typically entail platinum‐based chemotherapy in conjunction with cytoreductive surgery.
Zunera Khalid, Weirong Fan, Farah Nazir, Yixiang Xing, Tengchuan Jin   +4 more
wiley   +1 more source

PARP inhibitors chemopotentiate and synergize with cisplatin to inhibit bladder cancer cell survival and tumor growth

BMC Cancer, 2022
Background Management of bladder cancer (BLCA) has not changed significantly in the past few decades, with platinum agent chemotherapy being used in most cases.
Sayani Bhattacharjee, Matthew J. Sullivan, Rebecca R. Wynn, Alex Demagall, Andrew S. Hendrix, Puneet Sindhwani, Firas G. Petros, Nagalakshmi Nadiminty   +7 more
doaj   +1 more source

Comparative Efficacy and Safety of Poly (ADP-Ribose) Polymerase Inhibitors in Patients With Ovarian Cancer: A Systematic Review and Network Meta-Analysis

Frontiers in Oncology, 2022
ObjectiveThis study aims to compare the efficacy and safety of different poly (ADP-ribose) polymerase (PARP) inhibitors in patients with ovarian cancer through a network meta-analysis to support clinical treatment choices.MethodsThe Cochrane Library ...
Jing Luo, Shunlong Ou, Hua Wei, Xiaoli Qin, Qian Jiang   +4 more
doaj   +1 more source